Molecular Pharmacology of T-Type Calcium Channels and Their Roles in Neurological Disorders

Voltage-gated ion channels play important physiological roles by regulating the electrical activity of a range of different cell types through maintaining the gradients of different ions. Among these, voltage-gated calcium channels mediate various cellular activities, including muscle contraction, gene regulation, and neurotransmission. A sub-type of calcium channels are T-type calcium channels that play a critical role in regulating neuronal excitability and are essential for neurodevelopment. Mutations in genes encoding T-type calcium channels, including CACNA1G, CACNA1H, and CACNA1I can lead to altered channel activity, resulting in disrupted calcium entry, calcium signaling, synaptic plasticity, and neuronal differentiation. They have been implicated in a range of neurodevelopmental disorders, such as epilepsy, autism spectrum disorder, and intellectual disability. There has been considerable interest in developing blockers against T-type calcium channels to restore the dysregulated calcium homeostasis in neuronal disorders. T-type calcium channel blockers, originally developed for cardiovascular diseases, have emerged as potential therapeutic agents for neurodevelopmental disorders by targeting aberrant calcium signaling. This review explores the molecular mechanisms underlying T-type channel dysfunction caused by genetic mutations and evaluates the current evidence on the therapeutic efficacy of T-type calcium channel blockers in neurodevelopmental disorders. Although preclinical studies show promise, translating these findings into effective clinical therapies presents significant challenges. Future research focusing on optimizing blocker specificity and understanding the broader impact of channel modulation is necessary for developing targeted treatments for neurological pathologies.